Interleukin-6-Related Inflammatory Burden in Type 1 Diabetes: Evidence for Elevation with Suboptimal Glycemic Control

Area of Science:

• Endocrinology
• Immunology
• Metabolic Regulation

Background:

• Inflammation is a key feature of diabetes.
• Interleukin-6 (IL-6) links immune activation and metabolic regulation.
• The role of IL-6 in glycemic control across diabetes subtypes is not well understood.

Purpose of the Study:

• To investigate the relationship between IL-6 levels and glycemic control in type 1 diabetes (T1D) and type 2 diabetes (T2D).
• To explore IL-6 as a potential biomarker for systemic inflammation in diabetes management.

Main Methods:

• A cross-sectional pilot study involving 82 participants, including healthy controls, T1D, and T2D subgroups stratified by glycated hemoglobin (HbA1c) levels.
• Collected demographic, anthropometric, and laboratory data, including IL-6, hs-CRP, ferritin, and presepsin.
• Performed group comparisons adjusted for age and BMI, and correlation analyses using Spearman's rank correlation.

Main Results:

• IL-6 levels were ~4-fold higher in T1D individuals with HbA1c ≥ 7% compared to controls (p=0.013).
• No significant differences in IL-6 were observed in T2D groups.
• IL-6 showed a positive correlation with hs-CRP (ρ = 0.463, p < 0.001).

Conclusions:

• Elevated IL-6 concentrations in suboptimally managed T1D suggest poor glycemic control exacerbates systemic inflammation.
• IL-6 may serve as a biomarker for inflammatory burden in T1D.
• Further longitudinal studies are warranted to confirm IL-6's clinical utility in T1D.